A C57BL/6 Mouse model of SARS-CoV-2 infection recapitulates age- and sex-based differences in human COVID-19 disease and recovery

doi:10.21203/rs.3.rs-2194450/v1

Download PDF

Article

A C57BL/6 Mouse model of SARS-CoV-2 infection recapitulates age- and sex-based differences in human COVID-19 disease and recovery

https://doi.org/10.21203/rs.3.rs-2194450/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

We present a comprehensive analysis of SARS-CoV-2 infection and recovery in wild type C57BL/6 mice, demonstrating that this is an ideal model of infection and recovery that accurately phenocopies acute human disease arising from the ancestral SARS-CoV-2. Disease severity and infection kinetics are age- and sex-dependent, as has been reported for humans, with older mice and males in particular exhibiting decreased viral clearance and increased mortality. We identified key parallels with human pathology, including intense virus positivity in bronchial epithelial cells, wide-spread alveolar involvement, recruitment of immune cells to the infected lungs, and acute bronchial epithelial cell death. Moreover, older animals experienced increased virus persistence, delayed dispersal of immune cells into lung parenchyma, and morphologic evidence of tissue damage and inflammation. Parallel analysis of SCID mice revealed that the adaptive immune response was not required for recovery from COVID disease symptoms nor early phase clearance of virus but was required for efficient clearance of virus at later stages of infection. Finally, transcriptional analyses indicated that induction and duration of key innate immune gene programs may explain differences in age-dependent disease severity. Importantly, these data demonstrate that SARS-CoV-2-mediated disease in C57BL/6 mice accurately phenocopies human disease across ages and establishes a platform for future therapeutic and genetic screens for not just SARS-CoV-2 but also novel coronaviruses that have yet to emerge.

Biological sciences/Immunology/Infectious diseases

Biological sciences/Immunology/Infectious diseases/Viral infection

With the current SARS-CoV-2 pandemic, humans have now experienced three coronavirus (CoV) outbreaks in the last 20 years (SARS-CoV-1, MERS, SARS-CoV-2), and additional coronavirus outbreaks are expected in the future. Animal model systems are powerful tools to uncover mechanisms of pathology and to identify genetic dependencies for viral disease. Compared to non-human primates, ferrets, and other less widely used rodents, laboratory mice are the gold standard animal models of virus infection and disease course, in part as they permit genetic screens aimed at identifying immune factors and pathways required for disease and recovery. Complicating animal studies though, the ancestral strain SARS-CoV-2 did not naturally infect mice at the time of emergence, which was true for MERS and SARS-CoV-1 as well [1, 2]. For SARS-CoV-1 and SARS-CoV-2, this host restriction is due to sequence polymorphisms in murine Ace2 [3], the main receptor that binds viral Spike protein and permits cellular entry. To address this problem, researchers have used a transgenic mice expressing human ACE2 under the control of the keratin 18 promoter (K18-Ace2). These mice can be infected with ancestral SARS-CoV-2 and subsequent viral variants wherein they can develop severe pulmonary disease [4, 5]. However, due to ectopic expression of ACE2, these mice suffer from lethal neuroinflammation, a feature that is not seen in humans with COVID-19. Moreover, the hAce2 model complicates host genetic screens as knockout strains of interest must first be bred to the K18-Ace2 line. These limitations drove work to develop SARS-CoV-2 infection models in wild type (WT) mice using mouse-adapted (MA) viral variants [6–8, 3, 9–13]. Studies employing mouse-adapted SARS-CoV-2 strains have primarily been performed in BALB/c mice [6, 14, 9, 8, 13] and focused on a single sex or single age cohorts [10, 3, 12], or have employed highly adapted and virulent variants that limit the ability to comprehensively examine infection and recovery [11].

The SARS-CoV-2 pandemic is moving towards an endemic phase and is likely to remain a persistent threat as the viral genome continues to evolve [15]. Viral evolution of SARS-CoV-2 leads to the continual emergence of new variants of concern replacing previous circulating variants [16], and also led to the ability of SARS-CoV-2 variants to infect mice [17–19]. Additionally, current SARS-CoV-2 variants mediate a disease course that is much less pathogenic than the ancestral strain and has transitioned from causing a severe lower respiratory tract infection to a relatively mild upper respiratory tract infection [15]. Despite the lessened pathogenicity of newer SARS-CoV-2 variants, there remains a need to understand the processes underlying infection and recovery. Moreover, it is important to note that despite the potential for deadly outcome of severe COVID-19, ~ 99% of people infected with SARS-CoV-2 throughout the pandemic recovered from infection with only mild to moderate disease or were asymptomatic (https://covid19.who.int/). Thus, there remains an important need for comprehensive in vivo analyses of SARS-CoV-2 infection models to understand the dynamics of infection and recovery that include the comparison of both age and sex. Such studies can then set the stage for future genetic screens aimed at identifying key immune pathways required for recovery. Therefore, the goal of the present study was to develop an immunocompetent mouse model of SARS-CoV-2 infection that displays main features of human infection and recovery, starting with ancestral SAR-CoV-2. Here, we comprehensively describe a C57BL/6 model of SARS-CoV-2 infection and show the utility of this model in examining acute infection, progression to disease, lung disease, and recovery. As a great many transgenic C57BL/6 lines exist that lack specific genes or express modified version of specific genes, we demonstrate that this model provides a platform for genetic interrogation of the virus/host interactions that control SARS-CoV-2 infection and immunity.

Virologic and histologic analysis of SARS-CoV-2 infection in C57BL/6 mice.

To characterize SARS-CoV-2 infection in C57BL/6 mice, we challenging mice with a previously described variant, SARS-CoV-2-MA10 (MA10) [3]. MA10 was generated from the ancestral Wuhan isolate of SARS-CoV-2 and contains two amino acid mutations within the receptor binding domain of the Spike protein (Q498Y/P499T) that permit binding of Spike to murine Ace2. This double mutant was then serially passaged in Balb/c mice ten times to generate MA10, which contains five additional mutations in NSP4 (T285I), NSP7 (K2R, E23R), Spike (Q493K), and ORF6 (F7S) and results in acute pulmonary disease in infected mice. Intranasal infection with the MA10 strain in Balb/c mice produces an acute and self-limiting pneumonia that was more severe in older animals and less severe in C57BL/6 mice [1]. To verify that MA10 could productively infect C57BL/6 mice, we challenged 10 wk-old male mice intranasally with 10³, 10⁴, or 10⁵ PFU MA10 or saline as a vehicle-only control. Mice were then monitored daily for changes in weight. As shown in Fig. 1A, while mice challenged with 10³ PFU MA10 virus did not lose weight, those challenged with 10⁴ or 10⁵ PFU MA10 exhibited ~ 15% weight loss 3 days post infection (dpi) and recovered by 7 dpi. It is noteworthy that mice infected with 10⁴ or 10⁵ PFU MA10 experienced a near identical weight loss/recovery trend, suggesting that mice can tolerate a wide range of infectious doses with similar outcomes.

We also collected tissue from infected mice and mock-infected (mock) controls for histology, RNA-in situ hybridization (RNA-ISH), and qPCR-based measurements of viral load. 10 wk-old C57BL/6 male mice were infected with 10⁴ PFU MA10 or saline. Tissues were collected on days 2, 4, and 6 post-challenge with mock-infected controls being collected on day 6 post-challenge. The experiment was performed with biological triplicates for each timepoint cohort except for the mock control for which we only had a single mouse. In addition to the lungs, we collected heart, kidneys, and intestines, as these express high levels of Ace2 and are common sites of pathology in patients with severe COVID. The intestinal tract was separated into stomach, duodenum, jejunum, ileum, cecum, and large intestines to determine if there was a preference for SARS-CoV-2 infection across gut tissues. We also collected liver and spleen. We quantified viral RNA by RT-qPCR for the nucleocapsid gene, N2, and for Orf1 (Fig. 1B). The highest level of viral RNA was detected in lung on day 2 post infection at 1.2 x 10⁸ copies N2 and 6.9 x 10⁶ copies Orf1 per µL RNA, with the viral RNA level dropping by several logs over the next 4 days. N2 RNA was also consistently detected at day 2 post infection in the stomach and cecum, perhaps as a result from inoculum being swallowed during intranasal infection. N2 RNA was detected inconsistently in the heart, spleen, and large intestines at day 2 post infection and from the spleen at day 4 post infection. Our inability to consistently detect Orf1 RNA in non-lung tissues is likely due to its lower abundance compared to N2 RNA such that Orf1 RNA likely falls below the limits of detection in our assay. The raw data for each mouse at each timepoint are presented in Supp. Tables 1–4.

To determine the localization of SARS-CoV-2 within the mouse lungs during the course of infection, we performed RNA-in situ hybridization (ISH) for the Spike-coding region, which detects intact virus, defective virions, free viral genome, and subgenomic fragments. At the tissue level, intense bronchial epithelial and wide spread alveolar staining were observed at day 2 post-infection (Fig. 1C), a pattern observed in humans but not Balb/c mice [3, 20]. By day 4, bronchial epithelial cell ISH staining had largely cleared and there was reduced ISH staining of cells in the airspaces. Finally, by day 6, only scattered cells in the airspaces were ISH-positive. At the cellular level, ISH-positive cells displayed intense staining of their entire cell body and also more focal cytoplasmic staining, possibly representing cytoplasmic virus-containing vacuoles. These intracellular staining patterns are also consistent with what has been observed in cultured cells infected with SARS-CoV-2 [21].

Within the tracheal and main bronchial epithelium at 2 days post-infection, individual infected cells were often identified adjacent to virus-negative neighbor cell, and in some bronchioles, a confluent sheet of infected epithelial cells were observed as abruptly transitioning to a sheet of uninfected cells (Supp. Figure 1A). Moreover, numerous virus-positive dying cells were detected in the bronchial lumen on day 2 post infection but largely absent at 4 days post infection, suggesting that infected bronchial cells may be shed into the lumen and indicating a mechanism by which infected cells may be eliminated. We also observed intense apical ISH staining of some airway epithelial cells without cytoplasmic labeling, which could represent surface adhesion of the virus without productive infection. Unlike the large swaths of spike-positive cells within the bronchi, signals in alveoli were often limited to individual cells, likely type II pneumocytes as has been reported previously [3]. Outside of the lung, SARS-CoV-2 virus was occasionally detected in some mediastinal lymph nodes and focally in the spleen of one animal. It was not detected in the heart, kidney, liver, or esophagus (Supp. Figure 1B).

To specifically determine sites of virus replication, we marked replicating virus using an RNA-ISH with a probe that detects the antisense transcript (template strand) of the spike gene (Supp. Figure 1C). The observed antisense signal was significantly weaker than that of the sense strand, reflecting the relative abundance of sense and antisense strands during infection [21]. As opposed to the diffuse cell body staining that was seen with the sense strand probe, the antisense signal was restricted to discrete foci within the cell, likely representing vacuolized virus-like particles observed by EM (Supp. Figure 2) that concentrate transcriptional machinery for viral replication [22] and shield the replicating virus from host antiviral sensors within the cytosol [23]. Consistent with an acute infection followed by viral clearance and recovery, replicating virus was only seen in the lung at day 2 post-infection and was not detected in lungs of 10 wk-old animals at day 4 or 6 post infection.

We also conducted a pathologic examination of all tissues collected from 10 wk-old C57BL/6 male mice infected with SARS-CoV-2-MA10 (Fig. 1D). As detected by RNA-ISH analysis, we observed frank cell death within the bronchial epithelium as well as cells that were shed into the bronchial lumen, a phenomenon that peaked on day 2 post infection and significantly decreased thereafter. Peak viral infection at day 2 also associated with prominent endovascular inflammation, with leukocytes attaching to and underlying the endothelium in numerous arterial and venous vessels. However, this marked early endovascular inflammation was not associated with direct viral infection of the blood vessels as determined by RNA-ISH (Fig. 1C & Supp. Figure 1). As disease progressed, both perivascular and peribronchiolar inflammatory cell infiltrates increased along with alveolar inflammatory infiltrates and pulmonary edema (Fig. 1D).

Together, these findings suggest that MA10-C57BL/6 model accurately captures the pathology, tropism, immune cell recruitment to lungs, and disease kinetics that are typical of humans with an acute infection from SARS-CoV-2 [20].

The MA10-R2G variant.

During subsequent expansion of MA10 in Vero cells, we isolated a variant with an R2G substitution in NSP7 (MA10-R2G, R2G henceforth) (Fig. 2A). Similar to MA10, infection of C57BL/6 mice with R2G caused maximum weight loss 3 days post infection with a recovery to normal weight by day 6 or 7 post infection (Fig. 2B-C). We found that infections with R2G produced a more consistent pattern of weight loss, with lower variability and reduced mortality when compared to MA10 (Fig. 2D-E). The improved consistency and reduced virulence of R2G in 10-wk old mice is advantageous in studying potentiating effects of viral infection in older animals and, moving forward, in genetic knockout lines. Therefore, we used the R2G variant in the remainder of the experiments in this study.

Age- and sex-dependent differences in weight loss and survival

In humans with COVID-19, older individuals and males in particular are more likely to develop severe and lethal disease [24–26]. To determine the age and sex dependence for SARS-CoV-2 infection of C57BL/6J mice, we infected both male and female young (10 wks), mature (20 wks), and elderly (2 yrs) C57BL6/J mice with 10³, 10⁴, or 10⁵ PFU R2G and monitored them daily for changes in weight (Fig. 3). Infection of 10 wk-old animals with 10³ PFU resulted in no weight loss, while infection with 10⁴ or 10⁵ PFU resulted in 10% weight loss. At all infection doses, the 10 wk-old animals experienced rapid recovery (Fig. 3A). In contrast, weight loss in 20 wk-old animals was increasingly severe for each dose compared to 10 wk-old animals (Fig. 3B), including significant weight loss in aged mice infected with the lowest dose of 10³ PFU. Moreover, there was a clear separation in weight loss curves for animals infected with 10⁴ and 10⁵ PFU, where animals infected with 10⁴ PFU had an average weight loss of 20% and those infected with 10⁵ PFU experienced an even greater degree of weight loss. Importantly, while none of the 10 wk-old mice infected with 10⁵ PFU succumbed to infection, 40% of the 20 wk-old animals infected with 10⁵ PFU succumbed to infection or reached the euthanasia criteria of 30% weight loss.

We predicted that the 2 year-old animals would be extremely sensitive to infection. Therefore, we initially dropped the dose range and infected 2-yr old mice with 10², 10³, or 10⁴ PFU (Supp. Figure 3). Indeed, 2 year-old males infected with as low as 10² PFU did not fully recovery and ended the 7-day study course with an average of 10% weight loss, while those infected with 10³ PFU exhibited an average of 25% weight loss, confirming increased sensitivity to SARS-CoV-2 infection at lower virus challenge doses. Moreover, all males infected with 10⁴ PFU succumbed to infection or reached the euthanasia criteria of 30% weight loss, occurring within day 5 post-infection. In contrast, 2 year-old female mice responded similarly to 20 wk-old females infected with 10³ or 10⁴ PFU but surprisingly without mortality. We repeated this study but increased the virus challenge dose range to 10³, 10⁴, or 10⁵ PFU (Fig. 3C). As in our prior experiment, female, 2 year-old mice responded similarly if not better in terms of weight loss than 20 wk-old mice at all virus challenge doses, and strikingly, none of the 2 year-old females succumbed to infection, suggesting that older female C57BL6/J mice are less sensitive to infection than 20 wk-old female mice. A similar result was reported for influenza infection in female mice [27]. As in humans, older male mice fared the worst following SARS-CoV-2 infection, with no mice surviving past day 5 post infection with 10⁴ PFU R2G. Together, these data demonstrate a clear age and sex-dependent difference in C57BL/6 mice in response to infection that mimics the epidemiology of COVID-19 in humans.

Age- and sex-dependent changes in virus persistence and localization.

To determine how age and sex affect the ability of mice to clear virus and recover from infection, 10 wk-, 20 wk-, and ~ 2 year-old mice were infected with 10⁴ PFU R2G; and lung, heart, kidney, spleen, liver, stomach, and duodenum were collected 2, 4, and 7 days post infection with tissues from mock-infected animals being collected on day 7, each including triplicate samples across cohorts. Viral load per tissue and time point as well as weight loss for each cohort are presented in Fig. 4. Of note, because a significant number of 2 year-old male mice succumbed to infection or met euthanasia criteria on day 5 post infection, the data for males on day 7 post-infection represent only the survivors. As such, data for day 7 males suffer from selection bias and likely under-represent the true extent of disease severity in older male mice.

The highest viral loads in 10 wk-old mice infected with 10⁴ PFU R2G were found in the lungs. At day 2 post infection, males had a higher viral load (5.7 x 10⁹ copies of N2 RNA per mg lung tissue) compared to females (2.5 x 10⁹ copies of N2 RNA per mg lung tissue). Subsequently, viral load dropped by four logs to 3.2 x 10⁵ and 4.9 x 10⁵ copies N2 RNA per mg lung tissue in males and females, respectively, by 7 dpi. Virus was also detected in the heart and stomach of males and females and in the spleens of females only at 2 dpi but not thereafter.

For 20 wk-old animals (Fig. 4B), we also detected the highest viral copy number in the lungs, with 7.1 x 10⁹ and 4.6 x 10⁹ viral copies per mg lung tissue in males and females, respectively, 2 dpi and dropping several logs by 7 dpi to 1.1 x 10⁷ and 4.8 x 10⁶ copies N2 RNA per mg tissue in males and females, respectively. While there was no significant difference in viral load when comparing male 20 wk-old animals to age-matched females (Fig. 4E), their average viral load at day 7 post infection was 19-fold higher (p = 0.0015, unpaired t test) than levels in 10 wk-old animals. Additionally, virus in 20 wk-old animals was detected in additional tissues and at later time points in comparison to 10 wk-old animals (Fig. 4 and Supp. Tables), indicating that older animals clear virus less effectively (Fig. 4D).

When males and females were averaged in 2 year-old mice, the pattern of lung viral load essentially reproduced that observed in the lungs of 20 wk-old mice (Fig. 4B-D). However, while 20 wk-old male and female mice had nearly identical viral RNA levels at each time point, the abundance of lung viral RNA in the 2 year-old male and female animals diverged, with males having more virus and females having less virus than the 20 wk-old animals at each time point (Fig. 4E). Additionally, quantitation of viral RNA abundance demonstrated an increase in the distribution and durability of virus in tissues from animals infected at ~ 2 year of age, with virus detected in every tissue assayed (see Fig. 4 and Supp. Tables). These observations are consistent with the sex- and age-dependent differences in weight loss and survival (see Fig. 3). Moreover, with higher viral loads at later time points and a greater distribution of virus-positive tissues, these data support the notion that, like humans, older mice are unable to efficiently clear virus.

RNA-ISH and Pathology of R2G infection in young, mature, and elderly mice

Next, we assessed the distribution of virus within the lungs of R2G-infected young, mature, and elderly mice by RNA-ISH (Fig. 5). ISG staining patterns for younger mice infected with R2G largely phenocopied that observed for mice infected with MA10. RNA-ISH for the Spike gene was most intense in bronchial epithelial cells 2 days post infection with widespread airspace involvement. We also observed virus-positive cells sloughed into the lumen of the bronchioles. The ISH staining distribution was greatly diminished on days 4 and 7 compared to day 2 post infection. However, relative to 10 wk-old animals infected with R2G, there was more widespread and persistent RNA-ISH signal in 20 wk-old and 2 year-old animals at 4 and 7 dpi. Interestingly, 20 wk-old and 2 year old male mice had more widespread RNA-ISH staining at day 7 compared to their female counterparts. Together, these data indicate that SARS-CoV-2 increasingly spreads within lungs of aged mice compared to young mice and more so in aged males.

We next conducted a pathologic examination of H&E-stained sections from mice infected with R2G (Fig. 6 & Supp. Figure 4). As noted above, the true extent of disease severity in 2 year-old males is likely underestimated at day 7 due to the loss of many of the infected males at day 5 post infection. Despite this dynamic in the aged male cohorts, infection with R2G led to a significant number of dead/dying cells within the bronchi of older mice. While there was no difference in the degree of cell death as animals aged, the severity of this pathology varied more in the older compared to young animals (Fig. 6A). We also noted a pronounced burst of endovascular inflammation on day 2 post-infection for all ages, (Fig. 6B-C) which tapered off through day 7 post-infection. Concurrent with the decrease in endovascular inflammation, there was a marked increase in perivascular and peribronchial inflammation (Fig. 6D-F), indicating that inflammatory cells were moving out of the vasculature and into the tissue during the course of the infection. While there were generally no age-dependent changes in vascular and bronchial inflammation scores due to infection, perivascular inflammation was significantly higher in 2 year-old mock-infected mice than younger mice (Fig. 6E-F), suggesting a greater degree of basal perivascular inflammatory cells in older animals, which may represent increased bronchus associated lymphoid tissue (BALT) in aged mice [28]). Despite the lack of apparent differences in inflammatory responses across ages, we identified a significant increase in interstitial pneumonia and pulmonary edema that was both infection- and age-dependent (Fig. 6G-H). Interestingly, in contrast to infection with MA10, infection with R2G did not cause edema in 10 wk-old animals, likely reflecting its attenuated virulence of this viral variant. Older mice infected with R2G, however, demonstrated significant edema and also had more histopathologic evidence of comorbidities, including amyloidosis, lymphoid hyperplasia/lymphoma, pulmonary adenomas, and hyaline glomerulopathy (Supp. Figure 5).

Dependence on innate immune response for disease recovery and early reductions in viral load

To evaluate the roles of innate and adaptive immunity in control of SARS-CoV-2 and recovery from disease, we compared wild type and SCID mice (Fig. 7), as SCID mice lack an adaptive immune response due to the absence of functional B- and T-cells but have an intact innate immune response for defense against virus infection. Male SCID mice were challenged with 10³, 10⁴, and 10⁵ PFU R2G and compared to 10 wk-old wild type C57BL/6 mice challenged with the same doses. Similar to wild type mice and for all infection inoculums tested, SCID mice experienced maximal weight loss at day 3 post infection, began to recover on day 4, and reached their pre-infection weight on day 6 (Fig. 7A). These results indicated that the adaptive B- and T-cell-mediated immune responses are dispensable for the ability to recover from acute SARS-CoV-2-disease as marked by weight loss.

To determine whether adaptive immune response is necessary for the clearance of SARS-CoV-2 or pathologies resulting from infection, we challenged SCID mice with 10⁴ PFU and collected tissue 2, 4, or 7 dpi. Viral load on days 2 and 4 post infection were indistinguishable from wild type animals. However, despite the ability of SCID mice to return to normal weight by day 7 post infection, SCID mice had an elevated viral load 7 days post infection compared to wild type animals (4.8 x 10⁷ and 3.2 x 10⁵, p = 0.04, 1-tailed t-test respectively) (Fig. 7B), indicating that adaptive immunity is necessary for clearance of virus at later infection time points. Furthermore, 10 wk-old SCID mice infected with R2G demonstrated a similar trend in tissue pathology compared to wild type 10 wk-old mice (Fig. 7C & Supp. Figure 6), with the most notable differences being increased endovascular inflammation at day 4 and decreased interstitial and peribronchovascular inflammation at day 7. These observations indicate that control of viral burden is a multiphasic process that is initiated by innate immune responses and that transitions to adaptive responses.

Innate immune activation

To determine if innate immune activation is triggered in response to SARS-CoV-2 infection in the C57BL/6 model, we interrogated innate immune gene expression using a custom NanoString innate immune activation and response gene mouse probe set and nCounter-based transcriptional analyses of the lung samples described above (Fig. 8). The probe set (which included assay controls and housekeeping genes (Supp. Table 2)) was designed to monitor innate immune activation through expression of (1) IRF3-target genes, (2) types 1 and III interferon (IFN), (3) interferon-stimulated genes (ISGs) that are known to respond to specific pathogen recognition receptors, and (4) select NFκB-responsive genes encoding inflammatory response mediators. Resulting mRNA counts were transformed to account for differences in library size and then assessed by principle component analysis (PCA) (Fig. 8A-D and Supp. Figure 7A-B). Sample separation across the first principal component was predominantly driven by the acute induction (upregulation) of specific genes in the panel following infection (Supp. Figure 7A); these included known IRF3-target genes Rsad (viroporin), Cxcl10, IFN-b, Isg15, Ifi44, and Ifit2 [29] and ISGs including Mx1, Mx2, Isg20, Oas1b, and others; parallel induction of Tnfα, IL6 and IL-1 was also detected. Gene expression across lung samples along this first principal component largely clustered by time point, with samples from 2 days post infection demonstrating the highest levels of innate immune gene induction; samples at day 4 and 7 shifted toward mock levels (Fig. 8A). Moreover, as shown in Fig. 8B, the spread of samples from left to right (PC1) also strongly correlated with viral load (presented in Fig. 4), suggesting that variation in expression levels of the innate immune genes measured here was primarily driven by viral burden. While PC2 explained far less of the total variation in the data set (6% vs 74.9%, PC2 vs PC1 respectively), we identified a major distinction along this axis that separated the 10 and 20 wk-old animals from the 2 year-old mice (Fig. 8C) due to differences in IL-18, Tlr4, Irf2, IL1a, IfngR1, Irf7, and IfnaR1 (Supp. Figure 7B).

Given the clear delineation between the oldest and youngest mice across the data set, we next considered the degree to which innate immune profiles differed at baseline. We note that based on pathology scores (discussed above, Fig. 6), 2 year-old mice had increased levels of inflammation at baseline. Comparison of gene expression levels suggested that these differences are associated with the elevated baseline levels of Tlr7(p = 0.0022), TnfRsf1B (p = 0.0022), Gm14446 (p = 0.0022), Irf7 (p = 0.0043), Mx1 (p = 0.0043), Cxcl10 (p = 0.008), Dhx58 (p = 0.008), Tnfa (p = 0.015), Ifih1 (p = 0.026), Rsad2 (p = 0.026), Ccl12 (p = 0.041), Isg15 (p = 0.041), Ifit2 (p = 0.041), Eeif2ak (p = 0.041) (Supp. Figure 8). To assess the degree to which these elevated levels of gene expression altered the output of the innate immune response in 2 year old mice, we calculated the log2-fold change for each gene by comparing expression levels at each time point with age-matched mock-infected animals (Fig. 8F). Our analyses indicated that despite the presence of baseline inflammation, 2 year old mice had significantly lower induction of innate immune genes at 2 days post-infection, including Il6, Ccl4, Cxcl10, Rig-I, Irf7, Ifna2, Oas1b, and Mx2. As we considered the impact of age more closely, we noted that while 10 wk-old animals clustered tightly at each time point (Compare Figs. 8A & C), there was little to no separation between 20-wk old mice at days 4 and 7 post infection. 2 year-old animals followed this pattern, with even less separation between days 4 and 7 post infection. These observations show that the resolution of the innate immune response was delayed in older animals. Indeed, several key antiviral effectors and inflammatory drivers remained upregulated at late infection time points in older mice when compared to the 10 w-old animals, including several that were poorly upregulated initially in the older cohort; these included Il6, Isg15, Cxcl10, and Ifit2. Taken together, our transcriptional analyses (1) indicated baseline inflammation was present in older mice, in agreement with pathology scores; (2) demonstrated key deficits in the acute innate immune responses in older mice; and (3) revealed incomplete resolution of the innate immune and inflammatory responses in older mice at 7 days post infection, when these responses in younger mice had already returned to baseline levels.

We provide a model of SARS-CoV-2 infection and recovery in C57BL/6 mice, featuring the attenuated mouse-adapted R2G virus strain. We present a robust and comprehensive comparison of early to late infection in young, mature, and elderly adult mice, both in males and females. Our analyses include assessments of virus density and localization, animal weight loss kinetics and mortality, disease pathology across multiple tissues, and innate immune responses. We show that as in humans [24–26], disease is mild and quickly resolved in young, healthy individuals; however, disease severity is age- and sex-dependent, with older animals (especially older males) showing greater sensitivity to lower virus challenge doses, increased mortality, increased virus persistence with systemic virus spread, and greater lung damage. We show that the magnitude of the innate immune activation displayed by innate immune gene induction is greatest in young mice and that virus and the innate immune/inflammatory responses persist longer in aged mice, suggesting that these altered response compared to young mice contribute to viral persistence and increased lung injury in elderly mice. Finally, we show through comparison of wild type and SCID mice that the innate immune response is the primary driver of weight recovery and early-stage viral control in vivo, while an intact adaptive response is still required for efficient virus clearance at later infection time points. Together, these data characterize the effects of SARS-CoV-2 infection in C57BL/6 mice, which are remarkably similar to those in humans [24–26, 20], as well as what was seen for the 2003 strain of SARS1 [30, 31]. Additionally, this study paves the way for future studies aimed at identifying key immune pathways that are required for recovery and disease pathology following infection with not only the original strain of SARS-CoV-2 but future emergent coronaviruses as well.

A number of excellent groups have previously reported model systems for the in vivo study of SARS-CoV-2 infection in mice. Early in the pandemic, these studies required the use of mice expressing human Ace2 since original isolates of SARS-CoV-2 did not infect mice due to differences in human and murine Ace2 [32, 33]. While informative, infections in these mice did not replicate human disease due to the inappropriate localization and expression of hAce2. As the pandemic progressed, several groups reported on mouse-adapted strains of SARS-CoV-2 that acutely infected mice and produced disease reflecting what was seen in humans at that time [6–8, 14, 3, 9–13]. Though several of these studies examined the effects of infection in C57BL6 mice [7, 3, 10–12] these were limited to single sex or age cohorts or employed strains of SARS-CoV-2 that were too virulent for elucidating immune mechanisms of recovery by genetic screens. Compared to the few studies in C57BL/6 mice, the most comprehensive early studies with mouse-adapted strains characterized infection in Balb/c mice [7, 3, 11, 13] which do not permit the vast number of genetic screens that are possible with transgenic and gene knockout lines on the C57BL/6 background. Important to our future goals of genetically dissecting key immune pathways for disease recovery of knockout mouse strains on the C57BL/6 background, the immune responses and disease severity observed in Balb/c and C57BL/6 mice are different. For example, Balb/c mice are skewed towards a Type II immune response, which may exacerbate disease as in severe COVID, while C57BL/6 mice are skewed toward a Type I antiviral/inflammatory immune response, which is needed for efficient clearance of virus [34]. This notion is supported by studies showing that Balb/c mice experience more severe disease compared to C57BL/6 mice of the same age [3]. This and other differences necessitated the more comprehensive study of SARS-CoV-2 infection in C57BL/6 mice presented here.

Interestingly, in addition to their usefulness in genetic screens, C57BL/6 mice may better reflect disease recovery in humans than Balb/c mice. Specifically, virus tropism in C57BL/6 lungs appears to more closely phenocopy that in humans, where intense staining was observed in bronchial epithelium in addition to the alveolar space. In contrast, SARS-CoV-2 does not apparently localize to the bronchial epithelium in Balb/c mice ([3, 20] and present study). Moreover, staining of bronchial epithelium in humans and C57BL/6 mice correlates with shedding of dying cells into the bronchial lumen ([3, 20] and present study). Whether this outcome is important in virus clearance or virus spread or in the increased disease pathology in Balb/c mice relative to C57BL/6 mice is unclear. While not necessarily exclusive to C57BL/6 mice, the prominent pulmonary edema and interstitial pneumonitis seen in the older mice in our study also corresponds with the pulmonary edema seen radiographically in humans, and suggests that this phase of injury may resemble the early stage of SARS-CoV-2 induced acute respiratory distress in humans underlying COVID-19 [35, 36]. Our finding that infection-mediated lung injury follows clearing of the virus, and that more extensive lung injury is observed in older mice that have delayed viral clearance, suggests that a robust innate immune response in young mice leads to rapid clearing of the virus and limits the immunopathology in the lung, processes that ascertain SARS-CoV-2 infection outcome in most humans. Together, these observations suggest that C57BL/6 mice accurately capture infection and outcome dynamics observed in humans.

Novel variants of SARS-CoV-2 have arisen faster than detailed studies aiming to characterize their properties can be completed before being replaced by a new emergent variant. In fact, more recent variants, including the current omicron variants, developed the ability to infect mice and rats [17–19], which share Ace2 sequence similarity in the residues to which SARS-CoV-2 binds. What drove this adaptation is uncertain, but it is interesting that cryptic SARS-CoV-2 variants were found in the sewers of New York City that contain mutations that are found in mouse adapted MA10 and R2G as well as in omicron [37]. However, while omicron is able to infect mice, it is important to note that omicron-induced disease is much different from that driven by the ancestral SARS-COV-2 and appears to preferentially infect upper airways as opposed to lower airways and with milder symptoms, both in humans and mice [17, 38, 18, 19]. Moreover, while the ability of omicron to infect mice provides the very important opportunity to study natural infections of current strains in vivo, this variant does not allow studies of recovery from the more severe infections and disease pathologies engaging the lower airway that better reflect those arising from the ancestral virus and earlier pandemic variants.

As with many viral infections in humans, older males are more sensitive to infection with SARS-CoV-2 than older females [39]. We show here that as in humans, older male mice are much more susceptible to infection than older female mice. Surprisingly, older female mice are less susceptible to infection than mature female mice. The cause of these differences are uncertain and can be revealed in further studies, but are held true over multiple independent experiments within this study. Such outcomes have also been similarly been reported for influenza A virus infection in mice [27]. Importantly, these observations further validate this model system as a relevant model for the study of SARS-CoV-2-mediated disease and recovery.

In conclusion, we present a comprehensive analysis of SARS-CoV-2 infection and recovery in C57BL/6 mice, showing responses, pathologies, tropism, distribution, and age- and sex-dependent differences in disease severity that mimic what was seen following infection with the original isolates of SARS-CoV-2, when the virus first emerged in humans. These observations serve as a basis from which future C57BL/6-based genetic screens can be compared. Additionally, due to the increased reproducibility of R2G over the parental MA10, infection of C57BL/6 mice with the R2G variant of SARS-CoV-2-MA10 is an ideal model for SARS-CoV-2 mediated disease and recovery.

Mice:

10 wk-old C57BL/6J mice (Jax #000664) were purchased from Jackson laboratories directly or bred in-house from animals purchased from Jackson laboratories. 20-wk old C57BL/6J mice were purchased from Jackson Laboratories at 10 wks of age and aged to 20 wks old. SCID (B6.Cg-Prkdc^scid/SzJ, #001913) mice were purchased from Jackson laboratories. 2 year-old C57BL/6 mice were obtained from the National Institute of Aging subsidized aging rodent colony at Charles River, Inc. Mice were housed with appropriate food, water, and enrichment in accordance with University of Washington’s Institutional Animal Care and Use Committee (UW IACUC) specifications. Mice were euthanized if they fell below 70% original weight or became otherwise moribund, consistent with previously published studies [8, 3], and all experimental protocols were approved by the UW IACUC (Protocol #4158-01 & #4158-03) in accordance with relevant guidelines and regulations and have been reported in accordance with ARRIVE guidelines.

Infections and monitoring:

Mice were anesthetized with Ketamine/Xylazine at roughly 80–100 mg/kg ketamine and 5–10 mg/kg xylazine. Anesthetized mice were inoculated intranasally with indicated doses of virus diluted in saline at a total volume of 50 µl or with 50 µl saline alone as a mock control. Mice were closely monitored following anesthetization until they recovered and then were monitored daily for changes in health and/or weight. Mice were also monitored daily by UW DCM staff to ensure the animals always had sufficient food and water and that cage conditions met approved standards.

Virus:

SARS-CoV-2 MA10 was kindly provided by Ralph S. Baric. A P3 stock was amplified to 8 x 10⁶ PFU/mL in VERO (USAMRIID) cells and sequence verified. Sequence analysis indicated an R2G mutation in NSP7.

RNA prep:

Tissue collected at necropsy was originally placed in RNA later (Thermofischer, AM7021), stored at 4° for 24 hrs to one week, and then transferred to -20° for longer storage. To process tissue, samples were transferred to 1 mL Trizol (Thermofischer, 15596018) in 2 mL Percellys hard tissue homogenization tubes (Cayman Chemical Co., 10011151). Samples were homogenized in a Percellys 24 Homogenizer using 1–3 cycles of 15” at 6500 rpm and placing samples on ice between cycles. RNA was then purified from the Trizol homogenate using the RNeasy 96 kit (Qiagen), according to manufacturer’s protocols.

Histology & RNA-ISH:

For each mouse a sample of lung was incubated in formalin at room temperature for at least seven days to fix tissue and inactivate virus. The fixed tissue was processed and embedded in paraffin. 5 µm sections were cut and stained with hematoxylin and eosin (H&E). Airway pathology was assessed in H&E stained sections to assess bronchial epithelial cell death (score: 0 = no dead cells, 1 = 1–5 dead cells, 2 = 6–10 dead cells, 3 = 11–20 dead cells and 4 = > 20 dead cells; scored for 10 400X fields per mouse lung); endarteritis, venulitis, and perivenule, peribronchial and periarterial inflammation (score 0 = none, 1 = 0–25% circumference with > 1 leukocyte cell layer, 2 = 26–50% circumference with > 1 leukocyte cell layer, and 3 = 50–100% circumference with > 1 leukocyte cell layer; scored for 10 400X fields per mouse lung); and interstitial pneumonitis and pulmonary edema (score = percentage of pulmonary alveolar parenchyma with septae expanded by leukocyte; scored for 10 100X fields).

RNA in situ hybridization (RNA-ISH) was performed on FFPE sections of mouse tissues using the V-nCoV2019-S probe (Catalog# 848561) for sense strand of the Spike gene and the V-nCoV2019-S-sense probe (Catalog# 845701O) for the antisense strand of the Spike gene. RNA-ISH signal was developed using the RNAscope™ 2.5 HD Assay – RED development kit (Catalog # 322350) from ACDBio Inc., and slides were counterstained with hematoxylin for tissue visualization.

For scoring of infected bronchioles, individual bronchiole profiles were assessed for the percentage of infected cells according to the scheme outlined in Supplemental Fig. 8. Each of these bronchioles was also assessed for a shedding phenotype defined as ≥ 10 ISH-positive detached cells within the bronchiole lumen.

nCounter and bioinformatic analyses:

nCounter was run according to manufacturer’s protocol and custom probe set (Supp. Table 8). RCC output files were assessed for technical QC flags using the nSolver software provided by NanoString. Raw reads were next collated from RCC output files into a single count matrix in Rstudio. Because our probe set was highly non-random by design, the number of observed counts for each gene probe were several orders of magnitude greater between mock animals and those acutely infected with SARS-CoV-2. As a result of these large differences in library size, we developed a custom approach for analysis of these data that avoided artifacts introduced by distribution-based normalization methods; our methods are conceptually related to the family of log-ratio transformations that address the compositional nature of sequence-based data.

To perform these analyses, we leveraged count data within each sample vector as an internal reference, against which we could compare all genes of interest. To do so, we first measured the coefficient of variation (CV) for all genes in the probe set, which included: genes of interest (GOI), housekeeping (HK) genes, positive controls (PCs) and negative controls (NCs). Reassuringly, positive control probes were the least variable of all genes assessed, which was expected given their role in measuring technical variation of the sample prep and assay itself, both of which are demonstrated to be low. We then used the calculated CVs to select the 3 housekeeping genes with the lowest variability. To obtain our within-sample reference value, we calculated the geometric mean of the 3 selected HK genes. We then “tethered” all count data from each sample to its within-sample reference, which we refer to as tethered gene counts (TGCs).

To visualize data in PCA space and calculate vectors for biplot analyses, we utilized the log2 value of the TGCs (Fig. 8A-D). To assess changes in individual genes across groups, we simply used the TGC values (Fig. 1E & Supp. Figure 9). In order to calculate log2 fold-change, we formed a ratio using the TGC for each GOI against its age-matched values from mock animals, and subsequently took the log2 of these values (Fig. 8F).

To calculate statistical significance, we first checked for normalcy of TGC within each gene/population to be tested using a Shapiro Test. Following BH correction for multiple tests, we observed all data to be normal. We subsequently performed 2-way ANOVA using age and days-post infection as variables of interest. These data were then assessed by Tukey’s post-hoc correction, and thus, all reported p-values are Tukey adjusted.

Author contributions

Michael A. Davis served as project lead; Michael A. Davis and Kathleen Voss infected, monitored, and necropsied mice; Kathleen Voss managed the mouse colony; Michael A. Davis, Andrew T. Gustin, Shreeram Akilesh, Kelly Smith, and Michael Gale Jr. wrote the manuscript. J. Bryan Turnbull processed tissue samples and aided in monitoring mice; Andrew T. Gustin developed R package for bioinformatic analysis of nCounter data; Megan Knoll purified RNA and analyzed RNA samples for viral reads; Kelly D. Smith conducted pathologic analyses; Shreeram Akilesh conducted and analyzed RNA-ISH; Tony Muruato assisted in weighing mice; Tien-Ying Hsiang generated R2G variant of MA10; Kenneth H. Dinnon III, Sarah R. Leist, and Ralph S. Baric generated the mouse adapted virus MA10; Warren Ladiges and Katie Nickel provided 2-yr old mice; Michael Gale Jr. supported this project.

Acknowledgments

We would like to heartily thank Rick Wells, Jay Bickell, and Lesley Colby of the UW ABSL3/BSL3 facility and Tony Hann of UW E&HS for all of their BSL3 support during this project as well as during the pandemic. Supported by NIH/NIAID grants AI151698 and AI158788 (MG) as well as AI110700 (RSB).

Data Availability Statement

Datasets used for the analyses in this study have either been added to supplementary files or can be requested from the corresponding author upon request.

Cockrell AS, Yount BL, Scobey T, Jensen K, Douglas M, Beall A, Tang XC, Marasco WA, Heise MT, Baric RS (2016) A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol 2:16226. doi:10.1038/nmicrobiol.2016.226
Roberts A, Deming D, Paddock CD, Cheng A, Yount B, Vogel L, Herman BD, Sheahan T, Heise M, Genrich GL, Zaki SR, Baric R, Subbarao K (2007) A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS pathogens 3 (1):e5. doi:10.1371/journal.ppat.0030005
Leist SR, Dinnon KH, 3rd, Schafer A, Tse LV, Okuda K, Hou YJ, West A, Edwards CE, Sanders W, Fritch EJ, Gully KL, Scobey T, Brown AJ, Sheahan TP, Moorman NJ, Boucher RC, Gralinski LE, Montgomery SA, Baric RS (2020) A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell 183 (4):1070–1085 e1012. doi:10.1016/j.cell.2020.09.050
Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE, Earnest JT, Keeler SP, Ritter JH, Kang LI, Dort S, Robichaud A, Head R, Holtzman MJ, Diamond MS (2020) Publisher Correction: SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nature immunology 21 (11):1470. doi:10.1038/s41590-020-0794-2
Sun SH, Chen Q, Gu HJ, Yang G, Wang YX, Huang XY, Liu SS, Zhang NN, Li XF, Xiong R, Guo Y, Deng YQ, Huang WJ, Liu Q, Liu QM, Shen YL, Zhou Y, Yang X, Zhao TY, Fan CF, Zhou YS, Qin CF, Wang YC (2020) A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. Cell host & microbe 28 (1):124–133 e124. doi:10.1016/j.chom.2020.05.020
Chen Q, Huang XY, Liu Y, Sun MX, Ji B, Zhou C, Chi H, Zhang RR, Luo D, Tian Y, Li XF, Zhao H, Qin CF (2022) Comparative characterization of SARS-CoV-2 variants of concern and mouse-adapted strains in mice. J Med Virol 94 (7):3223–3232. doi:10.1002/jmv.27735
Chen Y, Li C, Liu F, Ye Z, Song W, Lee ACY, Shuai H, Lu L, To KK, Chan JF, Zhang AJ, Chu H, Yuen KY (2022) Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model. Emerg Microbes Infect 11 (1):368–383. doi:10.1080/22221751.2022.2026741
Dinnon KH, 3rd, Leist SR, Schafer A, Edwards CE, Martinez DR, Montgomery SA, West A, Yount BL, Jr., Hou YJ, Adams LE, Gully KL, Brown AJ, Huang E, Bryant MD, Choong IC, Glenn JS, Gralinski LE, Sheahan TP, Baric RS (2020) A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586 (7830):560–566. doi:10.1038/s41586-020-2708-8
Muruato A, Vu MN, Johnson BA, Davis-Gardner ME, Vanderheiden A, Lokugamage K, Schindewolf C, Crocquet-Valdes PA, Langsjoen RM, Plante JA, Plante KS, Weaver SC, Debbink K, Routh AL, Walker D, Suthar MS, Shi PY, Xie X, Menachery VD (2021) Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge. PLoS biology 19 (11):e3001284. doi:10.1371/journal.pbio.3001284
Wang J, Shuai L, Wang C, Liu R, He X, Zhang X, Sun Z, Shan D, Ge J, Wang X, Hua R, Zhong G, Wen Z, Bu Z (2020) Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein & cell 11 (10):776–782. doi:10.1007/s13238-020-00767-x
Wong LR, Zheng J, Wilhelmsen K, Li K, Ortiz ME, Schnicker NJ, Thurman A, Pezzulo AA, Szachowicz PJ, Li P, Pan R, Klumpp K, Aswad F, Rebo J, Narumiya S, Murakami M, Zuniga S, Sola I, Enjuanes L, Meyerholz DK, Fortney K, McCray PB, Jr., Perlman S (2022) Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. Nature 605 (7908):146–151. doi:10.1038/s41586-022-04630-3
Yan F, Li E, Wang T, Li Y, Liu J, Wang W, Qin T, Su R, Pei H, Wang S, Feng N, Zhao Y, Yang S, Xia X, Gao Y (2022) Characterization of Two Heterogeneous Lethal Mouse-Adapted SARS-CoV-2 Variants Recapitulating Representative Aspects of Human COVID-19. Front Immunol 13:821664. doi:10.3389/fimmu.2022.821664
Zhang Y, Huang K, Wang T, Deng F, Gong W, Hui X, Zhao Y, He X, Li C, Zhang Q, Chen X, Lv C, Lin X, Yang Y, Sun X, Shi Z, Chen H, Zou Z, Jin M (2021) SARS-CoV-2 rapidly adapts in aged BALB/c mice and induces typical pneumonia. Journal of virology. doi:10.1128/JVI.02477-20
Gu H, Chen Q, Yang G, He L, Fan H, Deng YQ, Wang Y, Teng Y, Zhao Z, Cui Y, Li Y, Li XF, Li J, Zhang NN, Yang X, Chen S, Guo Y, Zhao G, Wang X, Luo DY, Wang H, Yang X, Li Y, Han G, He Y, Zhou X, Geng S, Sheng X, Jiang S, Sun S, Qin CF, Zhou Y (2020) Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 369 (6511):1603–1607. doi:10.1126/science.abc4730
Mullin S, Wyk BV, Asher JL, Compton SR, Allore HG, Zeiss CJ (2022) Modeling pandemic to endemic patterns of SARS-CoV-2 transmission using parameters estimated from animal model data. PNAS Nexus 1 (3):pgac096. doi:10.1093/pnasnexus/pgac096
Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G, Tambone V, Caruso A, Angeletti S, Zella D, Ciccozzi M (2021) Evolution patterns of SARS-CoV-2: Snapshot on its genome variants. Biochem Biophys Res Commun 538:88–91. doi:10.1016/j.bbrc.2020.10.102
Halfmann PJ, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer SM, Darling TL, Joshi A, Loeber S, Singh G, Foster SL, Ying B, Case JB, Chong Z, Whitener B, Moliva J, Floyd K, Ujie M, Nakajima N, Ito M, Wright R, Uraki R, Warang P, Gagne M, Li R, Sakai-Tagawa Y, Liu Y, Larson D, Osorio JE, Hernandez-Ortiz JP, Henry AR, Ciuoderis K, Florek KR, Patel M, Odle A, Wong LR, Bateman AC, Wang Z, Edara VV, Chong Z, Franks J, Jeevan T, Fabrizio T, DeBeauchamp J, Kercher L, Seiler P, Gonzalez-Reiche AS, Sordillo EM, Chang LA, van Bakel H, Simon V, Consortium Mount Sinai Pathogen Surveillance study g, Douek DC, Sullivan NJ, Thackray LB, Ueki H, Yamayoshi S, Imai M, Perlman S, Webby RJ, Seder RA, Suthar MS, Garcia-Sastre A, Schotsaert M, Suzuki T, Boon ACM, Diamond MS, Kawaoka Y (2022) SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603 (7902):687–692. doi:10.1038/s41586-022-04441-6
Shuai H, Chan JF, Hu B, Chai Y, Yuen TT, Yin F, Huang X, Yoon C, Hu JC, Liu H, Shi J, Liu Y, Zhu T, Zhang J, Hou Y, Wang Y, Lu L, Cai JP, Zhang AJ, Zhou J, Yuan S, Brindley MA, Zhang BZ, Huang JD, To KK, Yuen KY, Chu H (2022) Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 603 (7902):693–699. doi:10.1038/s41586-022-04442-5
Shuai H, Chan JF, Yuen TT, Yoon C, Hu JC, Wen L, Hu B, Yang D, Wang Y, Hou Y, Huang X, Chai Y, Chan CC, Poon VK, Lu L, Zhang RQ, Chan WM, Ip JD, Chu AW, Hu YF, Cai JP, Chan KH, Zhou J, Sridhar S, Zhang BZ, Yuan S, Zhang AJ, Huang JD, To KK, Yuen KY, Chu H (2021) Emerging SARS-CoV-2 variants expand species tropism to murines. EBioMedicine 73:103643. doi:10.1016/j.ebiom.2021.103643
Schifanella LaA, J. L. and Galli, M. and Corbellino, M. and Lai, A. and Wieking, G. and Grzywacz, B. and Klatt, N. R. and Haase, A. T. and Schacker, T. W. (2020) Massive viral replication and cytopathic effects in early COVID-19 pneumonia. arXiv. doi:10.48550/ARXIV.2005.00004
Lee JY, Wing PAC, Gala DS, Noerenberg M, Jarvelin AI, Titlow J, Zhuang X, Palmalux N, Iselin L, Thompson MK, Parton RM, Prange-Barczynska M, Wainman A, Salguero FJ, Bishop T, Agranoff D, James W, Castello A, McKeating JA, Davis I (2022) Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differences. Elife 11. doi:10.7554/eLife.74153
Sutherland H, Bickmore WA (2009) Transcription factories: gene expression in unions? Nat Rev Genet 10 (7):457–466. doi:10.1038/nrg2592
Diamond MS, Kanneganti TD (2022) Innate immunity: the first line of defense against SARS-CoV-2. Nature immunology 23 (2):165–176. doi:10.1038/s41590-021-01091-0
Abate BB, Kassie AM, Kassaw MW, Aragie TG, Masresha SA (2020) Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open 10 (10):e040129. doi:10.1136/bmjopen-2020-040129
Bechmann N, Barthel A, Schedl A, Herzig S, Varga Z, Gebhard C, Mayr M, Hantel C, Beuschlein F, Wolfrum C, Perakakis N, Poston L, Andoniadou CL, Siow R, Gainetdinov RR, Dotan A, Shoenfeld Y, Mingrone G, Bornstein SR (2022) Sexual dimorphism in COVID-19: potential clinical and public health implications. Lancet Diabetes Endocrinol 10 (3):221–230. doi:10.1016/S2213-8587(21)00346-6
Davies NG, Klepac P, Liu Y, Prem K, Jit M, group CC-w, Eggo RM (2020) Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med 26 (8):1205–1211. doi:10.1038/s41591-020-0962-9
Lu J, Duan X, Zhao W, Wang J, Wang H, Zhou K, Fang M (2018) Aged Mice are More Resistant to Influenza Virus Infection due to Reduced Inflammation and Lung Pathology. Aging Dis 9 (3):358–373. doi:10.14336/AD.2017.0701
Sminia T, van der Brugge-Gamelkoorn GJ, Jeurissen SH (1989) Structure and function of bronchus-associated lymphoid tissue (BALT). Crit Rev Immunol 9 (2):119–150
Grandvaux N, Servant MJ, tenOever B, Sen GC, Balachandran S, Barber GN, Lin R, Hiscott J (2002) Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. Journal of virology 76 (11):5532–5539. doi:10.1128/jvi.76.11.5532-5539.2002
Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, Smee DF, Barnard DL (2009) A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology 395 (2):210–222. doi:10.1016/j.virol.2009.09.023
Frieman M, Yount B, Agnihothram S, Page C, Donaldson E, Roberts A, Vogel L, Woodruff B, Scorpio D, Subbarao K, Baric RS (2012) Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease. Journal of virology 86 (2):884–897. doi:10.1128/JVI.05957-11
Israelow B, Song E, Mao T, Lu P, Meir A, Liu F, Alfajaro MM, Wei J, Dong H, Homer RJ, Ring A, Wilen CB, Iwasaki A (2020) Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. The Journal of experimental medicine 217 (12). doi:10.1084/jem.20201241
Winkler ES, Chen RE, Alam F, Yildiz S, Case JB, Uccellini MB, Holtzman MJ, Garcia-Sastre A, Schotsaert M, Diamond MS (2022) SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice. Journal of virology 96 (1):e0151121. doi:10.1128/JVI.01511-21
Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A (2004) Innate immune response in Th1- and Th2-dominant mouse strains. Shock 22 (5):460–466. doi:10.1097/01.shk.0000142249.08135.e9
Satturwar S, Fowkes M, Farver C, Wilson AM, Eccher A, Girolami I, Pujadas E, Bryce C, Salem F, El Jamal SM, Paniz-Mondolfi A, Petersen B, Gordon RE, Reidy J, Fraggetta F, Marshall DA, Pantanowitz L (2021) Postmortem Findings Associated With SARS-CoV-2: Systematic Review and Meta-analysis. Am J Surg Pathol 45 (5):587–603. doi:10.1097/PAS.0000000000001650
Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY (2020) Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol 15 (5):700–704. doi:10.1016/j.jtho.2020.02.010
Smyth DS, Trujillo M, Gregory DA, Cheung K, Gao A, Graham M, Guan Y, Guldenpfennig C, Hoxie I, Kannoly S, Kubota N, Lyddon TD, Markman M, Rushford C, San KM, Sompanya G, Spagnolo F, Suarez R, Teixeiro E, Daniels M, Johnson MC, Dennehy JJ (2022) Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater. Nat Commun 13 (1):635. doi:10.1038/s41467-022-28246-3
Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, Louca P, May A, Figueiredo JC, Hu C, Molteni E, Canas L, Osterdahl MF, Modat M, Sudre CH, Fox B, Hammers A, Wolf J, Capdevila J, Chan AT, David SP, Steves CJ, Ourselin S, Spector TD (2022) Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet 399 (10335):1618–1624. doi:10.1016/S0140-6736(22)00327-0
Klein SL, Flanagan KL (2016) Sex differences in immune responses. Nat Rev Immunol 16 (10):626–638. doi:10.1038/nri.2016.90

No competing interests reported.

Download PDF

Version 1

posted

You are reading this latest preprint version

A C57BL/6 Mouse model of SARS-CoV-2 infection recapitulates age- and sex-based differences in human COVID-19 disease and recovery

Status:

Version 1

Abstract

Figures

Introduction

Results

Age- and sex-dependent differences in weight loss and survival

RNA-ISH and Pathology of R2G infection in young, mature, and elderly mice

Dependence on innate immune response for disease recovery and early reductions in viral load

Innate immune activation

Discussion

Materials And Methods

Mice:

Infections and monitoring:

Virus:

RNA prep:

Histology & RNA-ISH:

nCounter and bioinformatic analyses:

Declarations

Author contributions

Acknowledgments

References

Additional Declarations

Supplementary Files

Status:

Version 1